The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Osteoporosis Drugs Don’t Reduce Overall Mortality

Osteoporosis Drugs Don’t Reduce Overall Mortality

August 21, 2019 • By Megan Brooks

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Anti-fracture medications do not reduce overall mortality in older patients with osteoporosis, according to an updated systematic review and meta-analysis.

You Might Also Like
  • Abaloparatide-SC May Reduce Fractures for Osteoporosis & New FDA Safety Website
  • Osteoporosis Drugs Tied to Lower Fracture Risk & Health Costs
  • Women on Osteoporosis Drugs Still Need Bone Density Screenings

“This meta-analysis suggests drug treatments, including treatment with bisphosphonates, for osteoporosis should be recommended only for the prevention of fracture and not for any additional reduction in mortality,” researchers write in JAMA Internal Medicine, online Aug. 19.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In an email to Reuters Health, first author Steven Cummings, MD, FACP, of the University of California, San Francisco, notes that “many observational studies have reported, and many experts believe, that taking bisphosphonates, the most common treatment for osteoporosis, reduces mortality and doctors may be hearing that. If it is true, then clinicians should prescribe them to all older patients, regardless of their risk of fracture. We found that the most rigorous studies, randomized trials, don’t support that. Clinicians should prescribe them only to reduce fracture risk.”

The meta-analysis included 38 randomized, placebo-controlled clinical trials that studied drug treatments with proven anti-fracture efficacy, used agents at the approved dose for treatment of osteoporosis and had a duration of at least one year.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The trials included more than 100,000 adults with osteoporosis, with 45,594 randomized to placebo and 56,048 to treatment. There was no significant association between receiving a drug treatment for osteoporosis and overall mortality rate (risk ratio: 0.98; 95% confidence interval, 0.91 to 1.05; P=0.56), the researchers report.

There was no evidence for heterogeneity of the associations with mortality, even though the studies included diverse types of drugs (bisphosphonates, denosumab, selective estrogen receptor modulators, parathyroid hormone analogues, odanacatib and romosozumab).

An analysis limited to 21 clinical trials of bisphosphonate treatments, with 20,244 taking placebo and 22,623 active treatment, also found no significant association of treatment with overall mortality (risk ratio: 0.95; 95% CI, 0.86 to 1.04; P=0.17).

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

In the six trials of zoledronate, with 6,944 taking placebo and 6,926 active treatment (5 mg of zoledronate every 12 to 18 months), the overall mortality rate was also not statistically significant (risk ratio: 0.88; 95% CI, 0.68 to 1.13; P=0.31). However, there was evidence for heterogeneity of the results, the researchers say.

This meta-analysis, they note, is much larger and includes many more recent clinical trials than a meta-analysis from 2010 that found a 10% reduction in mortality. It also explored subgroups of drug therapies, specifically, zoledronate treatments, as well as clinical trials lasting three years or more.

The current meta-analysis also differs from a more recent one of 61 clinical trials of bisphosphonate treatments that also reported a 10% overall reduction in mortality. However, the analysis included 32 clinical trials for cancer and only 22 for osteoporosis as well as clinical trials without placebo controls, Dr. Cummings and colleagues point out.

Pages: 1 2 | Single Page

Filed Under: Conditions Tagged With: Fractures, mortality, Osteoporosis, osteoporosis treatments

You Might Also Like:
  • Abaloparatide-SC May Reduce Fractures for Osteoporosis & New FDA Safety Website
  • Osteoporosis Drugs Tied to Lower Fracture Risk & Health Costs
  • Women on Osteoporosis Drugs Still Need Bone Density Screenings
  • Abaloparatide vs. Alendronate for Osteoporosis

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.